Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2BTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3MPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PPARGSLC6A2SLC6A3SLC6A4SMOTYK2pol
The experimentally established mechanism targets of Maleic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 5/20 | 0.53 |
| ▸ | PIK3CD known ✓ | O00329 | 4/20 | 0.53 |
| ▸ | PIK3CA known ✓ | P42336 | 4/20 | 0.53 |
| ▸ | PIK3CB known ✓ | P42338 | 4/20 | 0.53 |
| ▸ | MTOR known ✓ | P42345 | 4/20 | 0.53 |
| ▸ | PIK3CG known ✓ | P48736 | 4/20 | 0.53 |
| ▸ | ERBB2 known ✓ | P04626 | 1/20 | 0.51 |
| ▸ | ERBB4 known ✓ | Q15303 | 1/20 | 0.51 |
| ▸ | LCK | P06239 | 16/20 | 0.59 |
| ▸ | SRC | P12931 | 16/20 | 0.57 |
| ▸ | TEK | Q02763 | 11/20 | 0.57 |
| ▸ | KDR | P35968 | 7/20 | 0.57 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.54 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.54 |
| ▸ | ABL1 | P00519 | 5/20 | 0.53 |
| ▸ | HCK | P08631 | 5/20 | 0.53 |
| ▸ | EPHB4 | P54760 | 4/20 | 0.53 |
| ▸ | PRKDC | P78527 | 4/20 | 0.53 |
| ▸ | PI4KB | Q9UBF8 | 4/20 | 0.53 |
| ▸ | FYN | P06241 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maleic Acid SCHEMBL6431001 | 1.00 | LCK (0.59) | LCKSRCTEKKDRLIMK1 | |
| Fumaric Acid SCHEMBL6434226 | 1.00 | LCK (0.59) | LCKSRCTEKKDRLIMK1 | |
| SCHEMBL4823873 | 0.96 | LCK (0.63) | LCKSRCTEKKDRLIMK1 | |
| SCHEMBL6434104 | 0.96 | LCK (0.63) | LCKSRCTEKKDRLIMK1 | |
| SCHEMBL4827919 | 0.88 | LCK (0.69) | LCKSRCTEKKDRLIMK1 | |
| SCHEMBL4827920 | 0.88 | LCK (0.69) | LCKSRCTEKKDRLIMK1 | |
| SCHEMBL6434045 | 0.88 | SRC (0.61) | LCKSRCTEKKDRLIMK1 | |
| SCHEMBL6431419 | 0.88 | SRC (0.61) | LCKSRCTEKKDRLIMK1 | |
| Fumaric Acid SCHEMBL4823009 | 0.87 | LCK (0.53) | LCKSRCTEKKDRLIMK1 | |
| Fumaric Acid SCHEMBL4823022 | 0.87 | LCK (0.53) | LCKSRCTEKKDRLIMK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6921763-B2 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2005-07-26 | — | — | US | disclosed |
| US-20050008640-A1 | Method of treating transplant rejection | ABBOTT LABORATORIES | 2005-01-13 | — | — | US | disclosed |
| US-6660744-B1 | Kinase inhibitors | ABBOTT GMBH & CO. KG (DE) | 2003-12-09 | — | — | US | disclosed |
| EP-1212327-B1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AG (DE) | 2003-08-20 | — | — | EP | disclosed |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2002-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050008640-A1 | Method of treating transplant rejection | LCK, ZAP70, FYN | EGFR 818/4885PIK3CD 470/4885PIK3CA 625/4885 |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | DPYD, CYP2D6, UGT1A1 | EGFR 2229/4885PIK3CD 1497/4885PIK3CA 419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.